46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-003016-23-IT (EUCTR) | 11/05/2011 | 07/03/2012 | Controlled randomized study on maintenance to low activity disease with low doses of SKA citokines compared with standard therapy | Controlled randomized study on maintenance to low activity disease with low doses of SKA citokines compared with standard therapy (DMARDS)of arthritis management - CIDAI STUDY | Rheumatoid Arthritis MedDRA version: 14.1;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Guna-Anti Interleukin 1 Product Code: NA INN or Proposed INN: NA Other descriptive name: Guna-Antiinterleukin 1 alfa INN or Proposed INN: NA Other descriptive name: Guna-Antiinterleukin 1 beta Product Name: Interleukin 10 Product Code: NA INN or Proposed INN: NA Other descriptive name: Guna-Interleukin 10 Product Name: Interleukin 4 Product Code: NA INN or Proposed INN: NA Other descriptive name: Guna-Interleukin 4 | GUNA SPA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy |